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The DAPI structure has been modiﬁed by replacing the phenyl group with substituted phenyl or het-
eroaryl rings. Twelve amidines were synthesized and their DNA binding, ﬂuorescence properties, in vitro
and in vivo activities were evaluated. These compounds are shown to bind in the DNA minor groove with
high afﬁnity, and exhibit superior in vitro antitrypanosomal activity to that of DAPI. Six new diamidines
(5b, 5c, 5d, 5e, 5f and 5j) exhibit superior in vivo activity to that of DAPI and four of these compounds
provide 100% animal cure at a low dose of 4  5 mg/kg i.p. in T. b. rhodesiense infected mice. Generally,
the ﬂuorescence properties of the new analogues are inferior to that of DAPI with the exception of
compound 5i which shows a moderate increase in efﬁcacy while compound 5k is comparable to DAPI.
© 2017 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Human African trypanosomiasis also known as sleeping sick-
ness is a neglected tropical disease in Sub-Saharan Africa caused by
two subspecies of Trypanosoma brucei (T. b. gambiense and T. b.
rhodesiense). It threatens over 65 million people among the poorest
in theworld in 36 countries [1a]. The trypanosomes are transmitted
mainly by blood-feeding tsetse ﬂies. Once infected, the disease
generally progresses through two stages which are deﬁned by the
location of the parasites in the patient. In the ﬁrst hemolymphatic
stage the parasites reside in the blood and lymph system whereas
in the second meningoencephalitic stage the parasites invade
additionally the central nervous system [1b]. It is generally
accepted that without an effective treatment the disease is lethal.
Drugs currently in use for sleeping sickness are pentamidine, sur-
amin, melarsoprol, and a combination of nifurtimox andy, Georgia State University,
r Masson SAS. This is an open acceeﬂornithine (NECT). The treatment selection is based on the sub-
species of T. brucei and on the disease stage. All drugs have disad-
vantages such as difﬁcult administration, serious side effects or
resistance issues. Better drugs are needed to control or eliminate
sleeping sickness. There are two new molecules, fexinidazole and
the oxaborole SCYX-7158 at the stage of clinical development [1c].
However, due to the high attrition rate in drug development it is
essential to continue with drug discovery to ﬁnd new drugs to cure
sleeping sickness.
Dicationic amidines that bind in the DNA minor groove are
promising agents against African trypanosomiasis. So far, pent-
amidine (Fig. 1) is the only one of this class which has seen sig-
niﬁcant human clinical use [2]. However, it is the most frequently
used drug for the treatment of ﬁrst stage sleeping sickness since
almost 8 decades and it is still effective by a parenteral route of
application.
DAPI (40, 6-diamidino-2-phenylindole) (Fig.1), was developed as
a compound related to diminazene and stilbamidine, to be used as
an antitrypanosomal agent [3]. DAPI has been subsequently found
to exhibit a variety of other biological effects, including antifungal,
antibacterial, and antiviral activities [3,4]. Also, DAPI is a ﬂuorescentss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Antitrypanosomal diamidines.
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been widely utilized as a DNA speciﬁc probe for ﬂow cytometry,
chromosome staining, DNA visualization and quantitation [6], and
has become now an important tool in molecular biology. We pre-
viously have reported some phenyl acetylene derivatives of DAPI
(compound I, Fig.1), that showed strong DNA binding and exhibited
potent in vitro activity superior to that of DAPI [7]. In a related
investigation, we extended the overall length of DAPI by adding one
phenyl group at the 5 or 6 position of indole and replacing the
phenyl group of DAPI with different aryl and heteroaryls (com-
pound II, Fig. 1), these diamidines showed strong DNA binding
comparable to that of DAPI and showed stronger in vitro anti-
trypanosomal activity with a comparable or stronger in vivo activity
than that of DAPI [8]. Moreover, we recently studied the replace-
ment of the indole ring of DAPI with a benzimidazole ring (com-
pound III, Fig. 1), these benzimidazole derivatives showed good
in vitro activity but exhibited very limited in vivo activity [9], which
demonstrated the importance of the indole ring of DAPI for the
antitrypanosomal activity. Here we report the replacement of the
phenyl ring of DAPI with different substituted phenyl and hetero-
aryl rings in anticipation of ﬁnding enhanced in vivo activity and
physicochemical properties.2. Results and discussion
2.1. Chemistry
Scheme 1 describes the preparation of the diamidines 5a-k in
good yield. 5 (6)-Cyanoindoles 1a,b were protected by employing
di-tert-butyldicarbonate in dichloromethane using 4-(dimethyla-
mino)pyridine as a catalyst. Lithiation of the Boc-protected indoles
2a,b was readily achieved with lithium diisopropylamide (LDA) in
anhydrous tetrahydrofuran at 20 C. Subsequent reaction of the
lithioindole intermediate with trimethyltin chloride gave the
indole stannanes 3a,b in good yield [10]. The stannane in-
termediates were allowed to react with different bromoaryl and
heteroaryl benzonitriles under Stille coupling conditions in the
presence of 5 mol % Pd(PPh3)4 using dioxane as a solvent to afford
the bisnitriles 4a-k in good yield. The bisnitriles 4a-kwere allowed
to react with lithium bis(trimethylsilyl)amide [11] in THF, followed
by deprotection of the silylated amidines with ethanolic HCl tofurnish the dihydrochloride salts of the diamidines 5a-k.
Scheme 2 illustrates the synthesis of the monoamidine 8. The
commercially available 1-bromo-4-methoxybenzene was coupled
with the indole stannane 2a utilizing Stille coupling conditions to
afford the mononitrile 7 in high yield. This mononitrile was con-
verted to the monoamidine hydrochloride 8 by utilizing the Pinner
methodology [12] by stirring in dry ethanolic HCl to yield the
imidate ester hydrochloride which was separated, dried and sus-
pended in ethanolic ammonia to furnish the monoamidine 8.2.2. Biology
Table 1 summarizes the DNA binding afﬁnities for the twelve
new amidino analogues of DAPI as well as both the in vitro and
in vivo activities of these compounds against Trypanosoma brucei
rhodensiense (T. b. r.). For comparative purposes, data for DAPI are
included. The thermal melting increase DTm (Tm of DNA-ligand
complex e Tm of free DNA) is a rapid and reliable method for
ranking binding afﬁnities for large numbers of aryldiamidines [13].
The DTm values for the complexes between poly (dA-dT) and the
new analogues vary with the change in the substitution of the 2-
aryl group and ranges from 10 to >26 C. The methyl 5b, methoxy
5d and the o-pyridyl 5e analogues exhibit high DTmvalues (>26 C)
comparable to that of DAPI. These three compounds have the
amidine group at the 6-position of indole, while their isomers with
the amidine group at 5-position (5a, 5c, 5f) of indole exhibit lower
DTm values.We hypothize that this decrease in DNA afﬁnity is likely
due to the fact that in the complex 6- amidino indole can form a
strong hydrogen bond involving the indole NH to a thymine
carbonyl as has been previously reported [7]. While in the analo-
gous complex for the 5-amidino indole such is not possible as the 3-
position CeH is pointed into the groove. Removal of the amidine
groups from DAPI as in the monoamidine 8 results in a big reduc-
tion of binding afﬁnity consistent with the loss of one key cationic
binding center.
Generally, heterocyclic diamidines have been found to bind in
the DNA minor groove in AT base pair sequences of DNA [14].Cir-
cular dichroism (CD) spectroscopy is a valuable technique for
characterizing minor groove interactions. In order to determine if
these new analogues bind in the DNA minor groove, we observed
the CD spectroscopy of complex formation. Fig. 2 shows the CD data
Scheme 1. Reagents and conditions. (a) Boc2O, DMAP, CH2Cl2; (b) ClSn(CH3)3, LDA/THF; (c) Br-Ar-CN, Pd(PPh3)4, Dioxane (d) 1-LiN(TMS)2/THF,2-HCl gas/EtOH.
Scheme 2. Reagents and conditions: (a) Pd(PPh3)4, Dioxane (b) i-HCl gas/EtOH.ii-NH3/EtOH.
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of DAPI as a reference compound. Minor groove binders yield a
large positive induced CD signal on binding to AT sequences and
only exhibit small changes in the CD pattern of the DNA spectrum.
The induced CD spectrum of DAPI is shown as a reference in
Fig. 2(a). The expected positive signal in the compound absorption
region with relatively small changes in the DNA region are
observed. The results shown in Fig. 2 shows that the CD data are
consistent with the D Tm results for 5d, 5e and 5j. Reﬂecting strong
binding to DNA, compound 5d exhibits large induced CD spectra in
its absorption regions that are higher than that for DAPI while 5e
and 5j exhibit comparable CD spectra to that of DAPI. This data
demonstrates the DNA minor groove binding of these compounds.
DAPI exhibits excellent in vitro activity against T. b. r (18 nM). All
of the newly synthesized compounds, except 5e and 8, showed an
in vitro activity stronger than that of DAPI ranging from a 2e6 fold
increase in activity. All the newly synthetized compounds showed
good selectivity indices ranging from 133 to 7833 indicating that
they are clearly less cytotoxic than DAPI (SI ¼ 48) with exception ofcompound 8 (SI ¼ 6), which was in vitro inactive versus T. b. r.
In view of the high in vitro activity and selectivity of these new
amidines, they were evaluated for efﬁcacy in the acute stage of
infection in the rigorous T. b. r. STIB900 mouse model (Table 1). The
compounds were tested by daily intraperitoneal dosage of 5 mg/kg
for four consecutive days. Four of the twelve new compounds (5d,
5e, 5f and 5j) cured all 4 infectedmice and gave 100% cure rate. Two
compounds (5b, 5c) cured 3 out of 4 mice and gave 75% cure rate,
while 5g and 5h gave 25% cure rate. Compound 5i was toxic killing
2 out of 4 mice and did not cure any of the two remaining mice. The
in vivo results for six compounds (5b, 5c, 5d, 5e, 5f and 5j) are
superior to that of DAPI and pentamidine that is in clinical use for
1st stage HAT since 80 years (both cure 2 out of 4 mice at 4  5 mg/
kg i.p.) in the STIB900 acutemousemodel and therefore the six new
compounds merit further evaluation as potential drug candidates
for HAT.
The widespread use of DAPI in molecular biology is in large part
due to its ﬂuorescence properties. During the study of these new
indole amidines we observed that several of the compounds were
Table 1
DNA binding, in vitro and in vivo antitrypanosomal activity of the DAPI analogues.
Compound Code DTma (

C) Cytotoxb (mM) T. b. rc (nM) SId In vivof(cures)
N
H
HN
NH2
NH
NH2
DAPI >27 0.86 18 48 2/4
H
N
NH
NH2
NH
H2N
5a 19.2 1.7 3 566 0/4
N
H
HN
NH2
NH
NH2
H3C 5b >26 15.7 5 3140 3/4
H
N
NH
NH2
NH
H2N
H3C 5c 15.3 23.5 3 7833 3/4
5d >26 29.6 6 4876 4/4
N
H
HN
NH2
N
NH
NH2
5e 22.1 3.2 24 133 4/4
5f >26 21.3 4 5325 4/4
N
H
HN
NH2
N
NH
NH2
5g 15.3 2.0 3 666.7 1/4
5h 12.1 1.8 5 394 1/4
N
H
HN
NH2
O
NH2
NH
5i 11 7.2 9 800 0/2
H
N
HN
NH2
NH
H2N O
5j 21.4 2.7 3 900 4/4
N
H
HN
NH2
S
NH2
NH
5k 10 4.5 11 409 0/4
8 12.6 29 4869 6 NDe
a Increase in thermal melting of poly (dA-dT)n.
b Cytotoxicity was evaluated using cultured L6 rat myoblast cells.
c The T. b. r. (Trypanosoma brucei rhodesiense) strain was STIB900. The values are the average of duplicate determinations.
d Selectivity Index for T. b. r. expressed as the ratio: IC50 (L6)/IC50 (T.b.r.).
e Not determined as in vitro inactive.
f In vivo efﬁcacy was determined in T. b. rhodesiense (STIB900) infected mice at 4  5 mg/kg i.p. dose.
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ﬂuorescence data for the new compounds and compare the results
with that of DAPI. These data are presented in Table 2.
The absorptionmaximum for the newamidines ranges from 312
to 370 nm; that for DAPI is 343 nm. The emission maximum ranges
from 418 to 493 nm in comparisonwith a value of 458 nm for DAPI.
A qualitative comparison of quantum yield of emission for the in-
doles shows that comp 5i shows a moderate increase in efﬁcacy
compared to that of DAPI while compound 5k is comparable to
DAPI. Both new diamidines have the advantage of being less cyto-
toxic than DAPI (Table 1). Compounds 5b, 5j and 8 shows 11e18%
decrease from that of DAPI, the rest of the compounds shows
signiﬁcantly lower quantum yield by a factor of 2e25.
3. Conclusion
The two diamidines, DAPI and pentamidine are highly active
against African trypanosomes. Substitutions on the phenyl ring of
DAPI or its replacement with heterocyclic rings results inFig. 2. Circular dichroism spectral proﬁles on the addition of representative compounds, wit
EDTA, at pH, 7.4).compounds that bind in the DNA minor groove with high afﬁnity
and exhibit superior in vitro antitrypanosomal activity to that of
DAPI. In vivo efﬁcacy of six newdiamidines (5b, 5c, 5d, 5e, 5f and 5j)
was further improved compared to that of DAPI, four of them gave
100% animal cures at the low dose of 4  5 mg/kg i.p. Generally,
there is a decline in the ﬂuorescence properties of the new ana-
logues compared to that of DAPI with the exception of compound 5i
that shows a moderate increase in efﬁcacy whereas compound 5k
is comparable to DAPI.
4. Experimental
4.1. Biology
4.1.1. Efﬁcacy studies
The in vitro viability assays [15] with the T. b. r. strain STIB 900 as
well as the efﬁcacy studies in the STIB900 acute mouse model for
T. b. r. at a 4  5 mg/kg i.p. dosage were carried out as previously
reported [16].h Poly (dA).Poly (dT) duplex DNA sequences in buffer (10 mMMES, 100 mM NaCl, 1 mM
Table 2
Fluorescence data for the new amidines.
Compound lexa,b (nm) lema,b (nm) Em. intensityc
DAPI 343 458 821
5a 322 481 176
5b 351 463 611
5c 341 461 33
5d 351 493 452
5e 348 470 461
5f 339 462 260
5g 342 480 53
5h 358 475 200
5i 322 418 875
5j 348 460 680
5k 370 481 810
8 312 433 690
a Wavelengths (l)are indicated for excitation (ex) and emission (em).
b Measurements were made with 0.001 M solutions in distilled water.
c Emission intensities were measured at excitation slit width of 5 and emission
slit width of 20.
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Thermal melting experiments were conducted with a Cary 300
spectrophotometer. Cuvettes for the experimentweremounted in a
thermal block and the solution temperatures monitored by a
thermistor in the reference cuvette. Temperaturesweremaintained
under computer control and increased at 0.5 C/min. The experi-
ments were conducted in 1 cm path length quartz cuvettes in CAC
10 buffer (cacodylic acid 10 mM, EDTA 1 mM, NaCl 100 mM with
NaOH added to give pH ¼ 7.0). The concentrations of DNA were
determined by measuring its absorbance at 260 nm. A ratio of
0.3 mol compound per mole of DNA was used for the complex and
DNA alone was used as a control [13]. DTm values were determined
by the peak in ﬁrst derivative curves (dA/dT).
4.1.3. Circular dichroism (CD)
CD spectra were collected employing a Jasco J-810 spectrometer
at different ratios of compound to DNA at 25 C in MES 10 buffer
(10 mMMES, 100 mM NaCl, I mM EDTA). A DNA solution in a 1-cm
quartz cuvette was ﬁrst scanned over the desired wavelength
range. DAPI, 5d, 5e and 5j at increasing ratios, were titrated into the
same cuvette and the complexes rescanned under the same con-
ditions [17].
4.2. Chemistry
All commercial reagents were used without puriﬁcation.
Melting points were determined on a Mel-Temp 3.0 melting point
apparatus, and are uncorrected. TLC analysis was carried out on
silica gel 60 F254 precoated aluminum sheets using UV light for
detection. 1H and 13C NMR spectra were recorded on a Bruker
400 MHz spectrometer (except as noted) using the indicated sol-
vents. Mass spectra were obtained from the Georgia State Univer-
sity Mass Spectrometry Laboratory, Atlanta, GA. If the compounds
reported as salts contain a fraction of water and/or solvents, these
fractions are seen in HNMR spectra. Elemental analysis were per-
formed by Atlantic Microlab Inc., Norcross, GA. Compounds 5a [18]
and 5d [19] were previously reported.
5. General procedure for the synthesis of the bisnitriles 4a-k
and 7
Tetrakistriphenylphosphine palladium (0.288 gm, 0.25 mmol)
was added to a stirred mixture of the indole stannane (3a or 3b)
(5 mmol) and the aryl halide (5 mmol) in de-aireated dioxane
(15 mL) under a nitrogen atmosphere. The vigorously stirredmixture was heated at 90e100 C for 24 h. The solvent was evap-
orated under reduced pressure, the resulting solid was partitioned
between ethyl acetate (200mL) and 5mL of concentrated ammonia
to remove the palladium complex, washed with water, passed
through celite to remove the catalyst, dried over sodium sulfate and
evaporated. Puriﬁcation by column chromatography on silica gel,
using hexanes/ethyl acetate (75/25, v/v).
5.1. 1-(tert-Butoxycarbonyl)-2-(2-methyl-4-cyanophenyl)-1H-
indole-6-carbonitrile (4b)
White solid, yield (1.98 gm, 75%). mp 164e164.5 C; 1HNMR
(CDCl3, 400 MHz) d 8.66 (s, 1H), 7.67 (d, 1H, J ¼ 8 Hz)760e7.58 (m,
2H), 7.55 (br d, 1H, J ¼ 8 Hz), 7.41 (d, 1H, J ¼ 8 Hz), 6.57 (s, 1H), 2.23
(s, 3H), 1.31 (s, 9H); 13CNMR (CDCl3, 100 MHz) d 156.4, 151.1, 149.2,
140.4, 137, 136.1, 132.5, 131.2, 130.0, 129.8, 127.6, 126.2, 125.1, 121.2,
121.1, 119.2, 112.8109.1, 104.2, 27.5, 21.5; ESI-MS: m/z calculated for
C22H19N3O2: 357.41, found: 358.2 (Mþþ1); Anal. Calcd. For
C22H19N3O2: C, 73.93; H, 5.36; N, 11.76. Found: C, 73.69; H, 5.32; N,
11.99.
5.2. 1-(tert-Butoxycarbonyl)-2-(2-methyl-4-cyanophenyl)-1H-
indole-5-carbonitrile (4c)
White solid, yield (0.85 gm, 66%), mp 191e193 C; 1HNMR
(DMSO-d6, 400 MHz) d 8.11 (d, 1H, J ¼ 1.5 Hz), 7.83 (s, 1H), 7.79 (dd,
1H, J ¼ 1.5 Hz, J ¼ 8.1 Hz), 7.74 (d, 1H, J ¼ 8.1 Hz), 7.58 (d, 1H,
J ¼ 8.4 Hz), 7.47 (dd, 1H, J ¼ 1.5 Hz, J ¼ 8.4 Hz), 6.88 (d, 1H,
J ¼ 1.5 Hz), 2.52 (s, 3H), 1.29 (s, 9H); 13CNMR (CDCl3, 100 MHz)
d 138.2, 137.7, 137.1, 135.9, 134.2, 129.6, 129.4, 127.7, 125.8, 124.5,
120.2, 118.4, 112.4, 110.4, 103.9, 101.5, 27.1, 21.3; ESI-MS: m/z
calculated for C17H11N3: 257 (Mþ).
5.3. 1-(tert-Butoxycarbonyl)-2-(5-cyanopyridin-2-yl)-1H-indole-6-
carbonitrile (4e)
White solid, yield (2.21 gm, 87%). mp 171e171.5 C; 1HNMR
(CDCl3, 400 MHz) d 8.96 (d, 1H, J¼ 1.2 Hz), 8.51 (s, 1H), 8.08 (dd, 1H,
J ¼ 2.0 Hz, J ¼ 8.0 Hz), 7.71 (d, 1H, J ¼ 8 Hz), 7.69 (d, 1H, J ¼ 8 Hz),
7.53 (dd, 1H, J ¼ 1.2 Hz, J ¼ 8 Hz), 6.95 (s, 1H), 1.44 (s, 9H); 13CNMR
(CDCl3, 400 MHz) d 155.2, 151.7, 148.8, 140.6, 139.4, 136.9, 131.6,
126.2, 123.1, 122.2, 119.8, 116.4, 112.3, 108.6, 109, 85.6, 27.6; ESI-MS:
m/z calculated for C20H16N4O2: 344.37, found: 345.2 (Mþþ1); Anal.
Calcd. For C20H16N4O2: C, 69.76; H, 4.68; N, 16.27. Found: C, 69.49;
H, 4.58; N, 16.08.
5.4. 1-(tert-Butoxycarbonyl)-2-(5-cyanopyridin-2-yl)-1H-indole-5-
carbonitrile (4f)
White solid, yield (2.06 gm, 81%). mp 180e181 C; 1HNMR
(CDCl3, 400MHz) d 8.65 (s,1H), 7.67 (s,1H, J¼ 8.0 Hz), 7.61e7.58 (m,
2H), 7.55 (dd, 1H, J ¼ 1.6 Hz, J ¼ 8.0 Hz), 7.41 (d, 1H, J ¼ 8.0 Hz), 6.57
(s, 1H), 1.31 (s, 9H); 13CNMR (CDCl3, 100 MHz) d 150.7, 148.9, 139.4,
137.0, 136.5, 133.3, 128.7, 128.5, 127.6, 125.9, 119.3, 117.0, 116.7112.0,
107.2, 86.2, 27.7; ESI-MS: m/z calculated for C20H16N4O2: 344.37,
found: 345.2 (Mþþ1); Anal. Calcd. For C20H16N4O2: C, 69.76; H,
4.68; N, 16.27. Found: C, 69.69; H, 4.81; N, 15.99.
5.5. 1-(tert-Butoxycarbonyl)-2-(6-cyanopyridin-3-yl)-1H-indole-6-
carbonitrile (4g)
White solid, yield (2.14 gm, 84%). mp 168e168.5 C; 1HNMR
(CDCl3, 400 MHz) d 8.81 (s, 1H), 8.35 (d, 1H, J ¼ 8.8 Hz), 7.97 (s, 1H),
7.92 (br d, 1H, J ¼ 8.0 Hz), 7.81 (d, 1H, J ¼ 8.0 Hz), 7.66 (d,1H,
J ¼ 8.8 Hz), 6.79 (s, 1H), 1.45 (s, 9H); 13CNMR (CDCl3, 100 MHz)
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119.3, 116.5, 112.4, 108.7, 108.7, 108.4, 85.6, 27.7; ESI-MS: m/z
calculated for C20H16N4O2: 344.37, found: 345.2 (Mþþ1); Anal.
Calcd. For C20H16N4O2: C, 69.76; H, 4.68; N, 16.27. Found: C, 69.66;
H, 4.62; N, 16.21.
5.6. 1-(tert-Butoxycarbonyl)-2-(6-cyanopyridin-3-yl)-1H-indole-5-
carbonitrile (4h)
White solid, yield (2.11 gm, 83%). mp 197e197.5 C; 1HNMR
(CDCl3, 400 MHz) d 8.81 (s, 1H), 8.34 (d, 1H, J ¼ 8.8 Hz), 7.97 (s, 1H),
7.93 (br d, 1H, J ¼ 8.0 Hz), 7.81 (d, 1H, J ¼ 8.8 Hz), 7.66 (d, 1H,
J ¼ 8.0 Hz), 6.79 (s, 1H), 1.44 (s, 9H); 13CNMR (CDCl3, 100 MHz)
d 150.8, 149.1, 139.7, 137.4, 136.3, 132.9, 128.9, 128.3, 127.5, 126.3,
119.2, 116.9, 116.8, 112.0, 107.2, 86.3, 27.7; ESI-MS:m/z calculated for
C20H16N4O2: 344.37, found: 345.2 (Mþþ1); Anal. Calcd. For
C20H16N4O2: C, 69.76; H, 4.68; N, 16.27. Found: C, 69.72; H, 4.66; N,
16.17.
5.7. 1-(tert-Butoxycarbonyl)-2-(5-cyanofuran-2yl)-1H-indole-6-
carbonitrile (4i)
Yellow solid, yield (1.58 gm, 64%). mp 154e155 C; 1HNMR
(CDCl3, 400MHz) d 8.3e8.15 (m, 2H), 7.81e7.74 (m, 2H), 7.20 (s, 1H),
7.14 (br s, 1H), 1.45 (s, 9H); 13CNMR (CDCl3, 100 MHz) d 150.7, 148.8,
148.6, 139.0, 129.3, 129.2, 128.3, 127.4, 125.4, 119.6, 116.3, 113.3,
112.7, 112.0, 106.4, 85.9, 27.5; ESI-MS: m/z calculated for
C19H15N3O3: 333.34, found: 334.2 (Mþþ1); Anal. Calcd. For
C19H15N3O3: C, 68.46; H, 4.54; N, 12.61. Found: C, 68.32; H, 4.61; N,
12.53.
5.8. 1-(tert-Butoxycarbonyl)-2-(5-cyanofuran-2yl)-1H-indole-5-
carbonitrile (4j)
Yellow solid, yield (1.7 gm, 69%). mp 162e162.5 C; 1HNMR
(CDCl3, 400 MHz) d 8.32 (d, 1H, J ¼ 8.4 Hz), 7.94 (s, 1H), 7.66e7.62
(m, 2H), 7.18 (d, 1H, J ¼ 3.6 Hz), 6.84 (s, 1H), 1.5 (s, 9H); 13CNMR
(CDCl3, 100 MHz) d 148.8, 141.5, 139.2, 136.9, 132.0, 128.5, 128.4,
128.3,125.8,119.3,116.6,113.7,110.5,112.9,107.0, 86.0, 27.7; ESI-MS:
m/z calculated for C19H15N3O3: 333.34, found: 334.2 (Mþþ1); Anal.
Calcd. For C19H15N3O3: C, 68.46; H, 4.54; N, 12.61. Found: C, 68.45;
H, 4.56; N, 12.6.
5.9. 1-(tert-Butoxycarbonyl)-2-(5-cyanothiophen-2yl)-1H-indole-
6-carbonitrile (4k)
Dark yellow solid, yield (1.83 gm, 71%). mp 181e181.3 C;
1HNMR (CDCl3, 400 MHz) d 8.31 (d, 1H, J¼ 8.8 Hz), 7.95 (s, 1H), 7.64
(d, 1H, J ¼ 8.8 Hz), 7.23 (d, 1H, J ¼ 3.6HZ), 6.95 (s, 1H), 6.76 (d, 1H,
J ¼ 3.6 Hz), 1.55 (s, 9H); 13CNMR (CDCl3, 100 MHz) d 158.8, 150.1,
148.6, 139.2, 129.3, 128.7, 128.1, 126.1, 123.1, 123.1, 119.2, 116.5, 112.6,
112.4, 111.2, 107.0, 85.8, 27.8; ESI-MS: m/z calculated for
C19H15N3O2S: 349.41, found: 349.3 (Mþþ1); Anal. Calcd. For
C19H15N3O2S: C, 65.31; H, 4.33; N, 12.03. Found: C, 65.28; H, 4.41; N,
11.99.
5.10. 1-(tert-Butoxycarbonyl)-2-(4-methoxyphenyl)-1H-indole-6-
carbonitrile (7)
White solid, yield (1.42 gm, 82%). mp 206e207 C as reported
[20]; 1HNMR (CDCl3, 400MHz) d 8.56 (s,1H), 7.61 (dd,1H, J¼ 2.0 Hz,
J ¼ 8.0 Hz), 7.51 (d, 1H, J ¼ 8 Hz), 7.36 (d, 2H, J ¼ 8.8HZ), 6.99 (d, 2H,
J ¼ 8.8HZ), 6.58 (d, 1H, J ¼ 2 Hz), 3.89 (s, 3H), 1.38 (s, 9H); 13CNMR
(CDCl3, 100 MHz) d 159.9, 149.6, 144, 136.3, 132.6, 130, 126.2, 126.1,
121, 119.9, 113.5, 109.2, 106, 84.7, 55.4, 27.6; ESI-MS: m/z calculatedfor C21H20N2O3: 348.4, found: 349.3 (Mþþ1); Anal. Calcd. For
C21H20N2O3: C, 72.40; H, 5.79; N, 8.04. Found: C, 72.35; H, 5.68; N,
8.12.
6. General procedure for the synthesis of the diamidines 5a-k
The dinitriles (4a-k) (0.66 mmol) were suspended in freshly
distilled THF (5 ml), and treated with lithium trimethylsilylamide
1M solution in tetrahydrofuran (4 ml, 3.98 mmol), the mixture was
stirred for three days at room temperature. The reaction mixture
was then cooled to zero oC and HCl saturated ethanol (2 ml) was
added. Themixturewas stirred for two days, diluted with ether and
the resultant solid was collected by ﬁltration. The diamidine was
puriﬁed by neutralization with 1 N sodium hydroxide solution
followed by ﬁltration of the resultant solid and washing with water
and dried. Finally, the free base was stirred with ethanolic HCl for
one week to make sure that the (Boc)2O group was completely
removed, diluted with ether, and the solid formed was ﬁltered and
dried to give the diamidines salt.
6.1. 2-(4-Amidino-3-methylphenyl)-1H-indole-6-amidine (5b)
Yellow solid, yield (0.149 gm, 61%), mp 277e279 C; 1HNMR
(DMSO-d6, 400 MHz) d 12.32 (s, 1H), 9.47 (s,2H), 9.32 (s,2H), 9.20
(s,2H), 8.96 (s,2H), 8.01 (s, 1H), 7.92 (s, 1H), 7.83e7.78 (m, 3H), 7.49
(d, 1H, J ¼ 8.4 Hz), 6.93 (s, 1H), 2.59 (s, 3H);; 13CNMR (DMSO-d6,
100 MHz) d 167.0, 165.6, 140.4, 137.1, 136.2, 132.6, 131.2, 130.0, 127.6,
126.2, 121.2, 121.1, 119.2, 112.8, 104.2, 21.6; ESI-MS: m/z calculated
for C17H17N5: 291.35, found: 292 (amidine base Mþþ1); Anal. Calcd.
For C17H17N5þ2HCl þ H2O: C, 53.41; H, 5.53; N, 18.31. Found: C,
53.15; H, 5.67; N, 18.12.
6.2. 2-(4-Amidino-3-methylphenyl)-1H-indole-5-amidine (5c)
pale solid, yield (0.130 gm, 53%), mp 285e287 C dec.; 1HNMR
(DMSO-d6, 400 MHz) d 12.39 (s, 1H), 9.55 (s, 2H), 9.35 (s, 2H), 9.32
(s, 2H), 9.12 (s, 2H), 8.23 (s, 1H), 7.93 (s, 1H), 7.87e7.82 (br s, 2H),
7.64 (br s, 2H), 6.95 (s, 1H), 2.59 (s, 1H); 13CNMR (DMSO-d6,
100 MHz) d 166.5, 165.1, 139.5138.1, 136.5, 136.4, 130.8, 129.3, 127.7,
126.9, 125.8, 121.7, 121.4, 118.7, 112.0, 104.5, 21.3; ESI-MS: m/z
calculated for C17H17N5: 291.35, found: 292 (amidine free base
Mþþ1); Anal. Calcd. For C17H17N5þ2HClþ0.25H2O: C, 55.37; H,
5.39; N, 18.99. Found: C, 55.46; H, 5.43; N, 18.72.
6.3. 2-(5-Amidinopyridine-2-yl)-1H-indole-6-amidine (5e)
Yellow solid, yield (0.171 gm, 71%), mp > 300 C; 1HNMR
(DMSO-d6, 400 MHz) d 12.65 (s, 1H), 9.70 (s,2H), 9.39 (s,2H), 9.13
(s,1H), 9.08 (s, 2H), 8.38 (br s,2H), 8.01 (s, 1H), 7.85 (d, 1H,
J ¼ 8.4 Hz), 7.51 (s, 1H), 7.46 (d, 1H, J ¼ 8.4 Hz); 13CNMR (DMSO-d6,
100 MHz) d 166.9, 162.0, 146.1, 143.1, 141.3, 136.1, 134.0, 132.3, 127.3,
124.5,122.1,118.9,113.2,104.3; ESI-MS:m/z calculated for C15H14N6:
278.31, found: 279.2 (amidine base Mþþ1); Anal. Calcd. For
C15H14N6þ2HClþ1.35H2Oþ 0.2 Et2O: C, 48.61; H, 5.34; N, 21.52.
Found: C, 48.29; H, 4.95; N, 21.24.
6.4. 2-(5-Amidinopyridine-2-yl)-1H-indole-5-amidine (5f)
Yellow solid, yield (0.157 gm, 65%), mp > 300 C; 1HNMR
(DMSO-d6, 400 MHz) d 13.0 (s, 1H), 9.70 (s, 2H), 9.50 (s, 2H), 9.48(s,
H), 9.33 (s, 2H), 9.09 (s, 2H), 8.76 (dd,1H, J ¼ 2.0 Hz, J ¼ 8.0 Hz), 7.51
(d, 1H, J ¼ 8.0 Hz), 8.26 (s, 1H), 7.69 (d, 1H, J ¼ 8.8 Hz), 7.67 (d, 1H,
J¼ 8.8 Hz), 7.55 (s, 1H); 13CNMR (DMSO-d6, 100 MHz) d 166.7, 161.9,
146.9, 142.6, 140.9, 136.0, 134.7, 131.9, 128.1, 124.0,122.6, 119.7, 112.7,
104.0; ESI-MS: m/z calculated for C15H14N6: 278.31, found: 279.4
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þ0.45Et2O: C, 48.7; H, 5.79; N, 20.28. Found: C, 48.81; H, 5.93; N,
19.99.6.5. 2-(6-Amidinopyridine-3-yl)-1H-indole-6-amidine (5g)
Yellow solid, yield (0.171 gm, 71%), mp > 300 C; 1HNMR
(DMSO-d6, 400MHz) d 12.85 (s,1H), 9.68 (s,2H), 9.48 (br s, 3H), 9.32
(s, 2H), 9.07 (s,2H), 8.74 (d,1H, J ¼ 8.4 Hz), 7.49 (d, 1H, J ¼ 8.4 Hz),
8.25 (s, 1H), 7.70 (d, 1H, J ¼ 8.4 Hz), 7.66 (d, 1H, J ¼ 8.4 Hz), 7.56 (s,
1H); 13CNMR (DMSO-d6,100MHz) d 166.4,162.9,146.9,142.7,140.9,
136.0, 134.4, 131.9, 128.2, 124.0, 122.7, 119.7, 112.7, 104.3; ESI-MS:m/
z calculated for C15H14N6: 278.31, found: 279.2 (amidine base
Mþþ1); Anal. Calcd. For C15H14N6þ2HClþ0.35H2O: C, 50.4; H, 4.7;
N, 23.5. Found: C, 50.72; H, 4.65; N, 23.16.6.6. 2-(6-Amidinopyridine-3-yl)-1H-indole-5-amidine (5h)
Yellow solid, yield (0.166 gm, 69%), mp > 300 C; 1HNMR
(DMSO-d6, 400 MHz) d 13.12 (s, 1H), 9.76 (s,2H), 9.51 (s,2H), 9.48
(s,1H), 9.33 (s, 2H), 9.10 (s,2H), 8.75 (d,1H, J ¼ 8.4 Hz), 7.51 (d, 1H,
J¼ 8.4 Hz), 8.26 (s, 1H), 7.71 (d, 1H, J¼ 8.8 Hz), 7.6 (d, 1H, J¼ 8.8 Hz),
7.56 (s, 1H); 13CNMR (DMSO-d6, 100 MHz) d 166.9, 162.1, 147.0,
142.7, 141.0, 136.0, 134.2, 132.0, 127.7, 124.1, 122.7, 119.9, 112.8, 104.3;
ESI-MS:m/z calculated for C15H14N6: 278.31, found: 279.2 (amidine
base Mþþ1); Anal. Calcd. For C15H14N6þ2HClþ0.3H2Oþ 0.2 Et2O: C,
51.08; H, 5.04; N, 22.62. Found: C, 50.94; H, 4.73; N, 22.94.6.7. 2-(5-Amidinofuran-2-yl)-1H-indole-6-amidine (5i)
Yellow solid, yield (0.173 gm, 49%), mp 277e279 C; 1HNMR
(DMSO-d6, 400 MHz) d 12.98 (s, 1H), 9.70 (s,2H), 9.39 (s,2H), 9.30
(s,2H), 9.07 (s,2H), 8.25 (s, 1H), 7.99 (d, 1H, J ¼ 3.6 Hz), 7.73 (d, 1H,
J ¼ 8.8 Hz), 7.64(b, 1H, J ¼ 8.8 Hz), 7.36 (d, 1H, J ¼ 3.6 Hz), 7.32 (s,
1H); 13CNMR (DMSO-d6, 100 MHz) d 166.7, 153.7, 151.6, 140.3, 140.1,
139.1, 130.0, 127.9, 122.7, 121.4, 119.7, 112.4, 110.0, 102.6,; ESI-MS:m/
z calculated for C14H13N5O: 267.29, found: 268.4 (amidine base
Mþþ1); Anal. Calcd. For C14H13N5O þ2HCl þ H2Oþ0.23Et2O: C,
47.75; H, 5.18; N, 18.66. Found: C, 47.62; H, 5.48; N, 18.28.6.8. 2-(5-Amidinofuran-2-yl)-1H-indole-5-amidine (5j)
Yellow solid, yield (0.159 gm, 45%), mp 263e265 C; 1HNMR
(DMSO-d6, 400 MHz) d 12.85 (s, 1H), 9.54 (s,2H), 9.42 (s,2H), 9.31
(s,2H), 9.17 (s,2H), 8.24 (s, 1H), 8.17 (d, 1H, J ¼ 4 Hz), 7.91 (d, 1H,
J ¼ 4 Hz), 7.64 (br s, 2H), 7.11 (br s, 1H); 13CNMR (DMSO-d6,
100 MHz) d 166.8, 158.9, 142.2, 140.5, 135.7, 133.3, 128.1, 127.7, 126.1,
122.6, 122.3, 119.8, 112.5, 102.6; ESI-MS: m/z calculated for
C14H13N5O: 267.29, found: 267.2 (amidine base Mþ); Anal. Calcd.
For C14H13N5O þ2HClþ2H2Oþ0.24Et2O: C, 45.6; H, 5.47; N, 17.77.
Found: C, 45.49; H, 5.62; N, 17.37.6.9. 2-(5-Amidinothiophen-2-yl)-1H-indole-6-amidine (5k)
Yellow solid, yield (0.14 gm, 58%), mp 281e283 C; 1HNMR
(DMSO-d6, 400 MHz) d 13.0 (s, 1H), 9.61 (s,2H), 9.30 (s,2H), 9.20
(s,2H), 9.03 (s,2H), 8.25 (s,1H), 8.02 (d, 1H, J ¼ 4 Hz), 7.76 (dd, 1H,
J¼ 1.2 Hz, J¼ 8.4 Hz), 7.61 (d,1H, J¼ 8 Hz), 7.36 (d,1H, J¼ 4 Hz), 7.33
(br s, 1H); 13CNMR (DMSO-d6, 100 MHz) d 166.8, 153.2, 151.9, 140.4,
140.1, 140.0, 130.1, 127.1, 122.9, 121.4, 120.1, 112.5, 110.3, 102.7; ESI-
MS: m/z calculated for C14H13N5S: 283.35, found: 284.1 (amidine
base Mþþ1); Anal. Calcd. For C14H13N5S þ2HClþ0.02H2O: C, 47.14;
H, 4.25; N, 19.63. Found: C, 46.96; H, 4.43; N, 19.39.6.10. 2-(4-methoxyphenyl)-1H-indole-6-amidine (8)
The mononitrile 7 (0.23 g, 0.66 mmol) was dissolved in satu-
rated ethanolic HCl (5 mL) and stirred at room temperature for 1
week, isolated from air and moisture. Dry ether was added, the
crystals which formed were ﬁltered, dried under vacuum for 1 h,
dissolved in absolute ethanol, ammonia gas was passed into the
solution for 30 min while cooling and the resulting solution was
stirred for 4 days at room temperature. Dry ether was added, the
precipitated crystals (HCl salt) were ﬁltered. The diamidine was
puriﬁed by neutralization with 1 N sodium hydroxide solution
followed by ﬁltration of the resultant solid and washing with water
and dried. Finally, the free base was stirred with ethanolic HCl
(5 mL) for 2 days at room temperature, diluted with ether, and the
formed solid was ﬁltered and dried.
White solid, yield (0.11 gm, 54%), mp 281e283 C; 1HNMR
(DMSO-d6, 400 MHz) d 12.03 (s, 1H), 9.26 (s, 2H), 8.97 (s, 2H), 7.92
(m, 3H), 7.69 (d, 1H, J ¼ 8.4 Hz), 7.44 (d, 1H, J ¼ 8.4 Hz), 7.08 (d, 2H,
J ¼ 8.4 Hz), 6.95 (s, 1H); 13CNMR (DMSO-d6, 100 MHz) d 167, 142.8,
137.2, 136.4, 133.5, 129.7, 127.7, 124.3, 120.3, 120, 119.2, 115, 112.2,
55.8; ESI-MS: m/z calculated for C16H15N3O: 265.31, found: 266.1
(amidine base Mþþ1); Anal. Calcd. For C16H15N3O þ1HClþ1.15H2O:
C, 59.59; H, 5.71; N, 13.03. Found: C, 59.35; H, 5.78; N, 13.01.
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